Patents Assigned to ProScan Rx Pharma Inc.
  • Patent number: 8629247
    Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: January 14, 2014
    Assignee: Proscan RX Pharma Inc.
    Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • Patent number: 8512702
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: August 20, 2013
    Assignee: Proscan Rx Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
  • Publication number: 20120093719
    Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.
    Type: Application
    Filed: April 14, 2010
    Publication date: April 19, 2012
    Applicant: PROSCAN RX PHARMA INC.
    Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
  • Publication number: 20120082618
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Application
    Filed: December 14, 2011
    Publication date: April 5, 2012
    Applicant: PROSCAN RX PHARMA INC.
    Inventors: CLAUDIO CUELLO, URI SARAGOVI, PIERRE DU RUISSEAU, PHIL GOLD, NICOLE BERNARD, SERGE MOFFETT
  • Patent number: 8101713
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: January 24, 2012
    Assignee: Proscan RX Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
  • Patent number: 7910693
    Abstract: The present invention relates to novel mimetopes of anti-PSMA antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastatis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: March 22, 2011
    Assignee: ProScan Rx Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Serge Moffett
  • Publication number: 20110064654
    Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Applicant: Proscan Rx Pharma Inc.
    Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett